Trinity Biotech PLC (TRIB) stock
TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$5.83−0.18 (-3.08%)
Close on Nov 18, 2026Market cap $108.99MP/E –Yield –
Trinity Biotech operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$15.79M. The highest annual figure on record is $13.51M in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$15.79M | – |
| FY2024 | Dec 31, 2024 | -$21.17M | – |
| FY2023 | Dec 31, 2023 | -$27.05M | – |
| FY2022 | Dec 31, 2022 | -$19.35M | -591.3% |
| FY2021 | Dec 31, 2021 | $3.94M | +4702.4% |
| FY2020 | Dec 31, 2020 | $82.00K | – |
| FY2019 | Dec 31, 2019 | -$24.11M | – |
| FY2018 | Dec 31, 2018 | -$20.23M | – |
| FY2017 | Dec 31, 2017 | -$37.67M | – |
| FY2016 | Dec 31, 2016 | -$39.85M | -395.0% |
| FY2015 | Dec 31, 2015 | $13.51M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2018 | Jun 30, 2018 | $1.73M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.83M | – |
See a number that looks wrong?